Tag: endoleak
Use of AI in endoleak detection deemed “feasible” with “potentially significant”...
A recently published retrospective study has shown that a deep learning model based on non-contrast computed tomography (CT) can detect endoleak after endovascular aneurysm...
Five-year results of the LEOPARD trial published in the Journal of...
Endologix has announced the online publication of the final five-year results of the LEOPARD trial in the Journal of Vascular Surgery (JVS). The study's...
Global discussion maps out future priorities for abdominal aortic aneurysm care
There was general agreement between physicians from across the globe that there is “work to do” in the way abdominal aortic aneurysm (AAA) sac...
Treatment of type I endoleak rests on ensuring chosen device outlives...
Anna Prent (London, UK) chats to Vascular News at London Aortic Symposium (11–12 October 2018, London, UK), about the need to treat type I...
Pre-emptive embolisation of aneurysm sac side branches prevents post-EVAR type II...
According to Daniela Branzan (University Hospital Leipzig, Leipzig, Germany) and colleagues, pre-emptive embolisation of aneurysm sac side branches for patients with abdominal aortic aneurysm...
Nearly 70% of CX 2020 LIVE global aortic audience finds type...
A global audience tuned into the second session and inaugural aortic offering of CX 2020 LIVE. With registrations now well over 4,000, the pioneering...
FDA updates advisory letter on device-related type III endoleak risks
An update to last year’s FDA letter, expressing concern over risk of type III endoleaks in relation to endovascular graft systems, now states that...
Enhanced outcomes found for Medtronic Heli-FX EndoAnchor patients with complex aortic...
Medtronic has announced data demonstrating that the company's Heli-FX EndoAnchor system enhances outcomes and durability in patients with complex aortic abdominal aneurysm (AAA) anatomy,...
No type Ia or III endoleaks at three years with Incraft...
Preliminary results from the INNOVATION study indicate that the device is not associated with any type Ia or type III endoleaks at three years for patients undergoing EVAR. Incraft shows a freedom from sac increase rate of 95.6%.
